SNMMI Nuclear Oncology Council
FY2015 Business Plan
(October 1, 2014 – September 30, 2015)

1) Executive Summary

The Nuclear Oncology Council continues its focus on the use and optimization of tracers for targeted imaging and therapy. By strategic planning and efforts of the key governing members we have furthered efforts in improving the knowledge and utilization of the current modalities and expanding the scope to newer applications.

Nuclear oncology council continues its efforts in increasing the use of diagnostic and therapeutic radiopharmaceuticals. The NOC continues to participate and conduct educational activities focusing on the use of conventional and non conventional tracers. NOC also is actively involved in understanding various issues that influence the clinical use and expansion of applications of the radiopharmaceuticals in diagnosis and therapy of malignancies. The NOC has initiated efforts to understand and participate in developing the guidelines for use of guidelines (NCCN) of PET tracers; RAI therapy in thyroid cancer and aim to lead the effort to make the change in the coming year. NOC holds several educational sessions in SNMMI Annual and Midwinter meetings to educate physicians, technologists, physicists and supportive staff on novel applications of radiopharmaceuticals. For example, practical aspects of administration of Xofigo treatments has been discussed in NOC organized sessions in midwinter and annual meeting. The audience receives SAM credits on many of the sessions organized by NOC. In the past year, NOC organized 1 categorical session and 7 CE sessions. There were joint sessions held collaboratively with the YIA and CMIT.

NOC is also making strong international impact by increased collaboration with WARMTH (World Association of Radiopharmaceutical and Molecular Therapy). NOC and WARMTH jointly organized CE programs in annual SNMMI meetings in 2013 and 2014 and midwinter SNMMI meeting in 2014; similar sessions are planned for 2015 SNMMI meetings also. This collaboration has proven extremely fruitful to enhance and exchange ideas, knowledge and experience across the globe. This collaboration has had a major impact on NOC activities both within SNMMI and internationally through WARMTH.

2) Mission of the Council

To be the recognized world leader in providing knowledge that advances and promotes the use of radiotherapeutic agents, devices and radiopharmaceuticals in molecular imaging, and which vigorously supports the expansion of clinical trials for such agents, devices, and/or radiopharmaceuticals.

The goals of the Council are to:

(a) Provide a forum for those members of the Society with an interest in nuclear oncology, both therapeutic and diagnostic;
• Providing an interactive NOC forum to ask, questions, queries, bring up and discuss issues.
• Identifying key contacts that can provide guidance and opinion
• Organizing educational sessions at SNMMI

(b) Provide an informational resource to support those involved in nuclear oncology;
• By providing online resources list on the website
• Providing key links to personnel, material and educational materials

(c) Support the development of diagnostic and therapeutic clinical trials;
• Initiatives to understand the utilization of the radiopharmaceuticals
• Participate and enhance knowledge in newer applications
• Participate in influencing guidelines development by task forces and focused efforts to participate as a member in the guidelines committees

(d) Support the educational objectives of the Society with respect to nuclear oncology;
• Organizing educational activities in SNMMI meetings
• Joint sessions with WARMTH
• Increase participation of SNMMI community in other meetings like ASCO, ASTRO, AACR via NOC organized sessions

(e) To represent the interests of practitioners of nuclear oncology to the Society; and
• Understand the administrative and practice based issues that influence the use of radiopharmaceuticals by interactive one on one discussions and organized educational sessions, e.g. with FDA, clinical trials groups, Industry
• Bring the clinicians and regulators in one forum

The Council will support clinicians, scientists, and technologists who are involved in the practice of oncological nuclear medicine and who seek to have a role in the development of the field, and benefit ongoing patient care.

3) Leadership

<table>
<thead>
<tr>
<th>Position</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>President: Neeta D. Pandit-Taskar, MD</td>
<td>2013 - 2015</td>
</tr>
<tr>
<td>Vice President: Suresh C. Srivastava, PhD</td>
<td>2013 - 2015</td>
</tr>
<tr>
<td>Vice President-Elect: Daniel Pyrma, MD</td>
<td>2013 - 2015</td>
</tr>
<tr>
<td>Treasurer/Secretary: Rathan Subramaniam, MD, PhD, MPH</td>
<td>2014 - 2016</td>
</tr>
<tr>
<td>Immediate Past-President: Gregory A. Wiseman, MD</td>
<td>2013 - 2015</td>
</tr>
</tbody>
</table>

**Board of Directors**

Andrei Iagaru, MD, FACNM 2014 - 2015
Sandy McEwan, MD 2014 - 2016
4) **Current Status**

The NOC is in good financial standing, and expects an estimated carry-over of $12,600 into fiscal year 2015. As of July 1, 2014, the NOC has 360 total paid members, which includes 242 physicians/scientists and 118 technologists. While current membership is growing, primarily due to technologist members, it is still lower than the 405 members in 2010. This no doubt is due to the current trends in the practice of Nuclear Medicine and the potential for diagnostic and therapeutic applications. The NOC Board will work to ensure continued growth in membership and participation.

**Membership Benefits**

The NOC provides a forum for the members to contribute to the development of the field of nuclear oncology by regular communications amongst the membership as well as collaboration and interaction during the special educational and administrative sessions during national meetings. The NOC also maintains a strong relationship with other organizations.

5) **Accomplishments**

The accomplishments of the Council over the preceding 12 months include:

1. Organized sessions for the SNMMI Annual and Mid-Winter Meeting
2. Published the council newsletter.
3. Nuclear Oncology Young Investigator Award (YIA). First, second and third place winners were announced during the NOC business meeting held during the SNMMI Annual Meeting. The objectives of this new award are to identify promising young investigators working in nuclear oncology-related fields within nuclear medicine.
4. Collaborative program for educational activities with WARMTH

6) **Goals and Programs**

The NOC contributes to the SNMMI Strategic Plan Goal B, facilitate and support the availability and clinical utilization of nuclear medicine and molecular imaging technologies; Goal C, increase appropriate utilization of radionuclide therapy; and Goal D, advance and promote quality, value and safety of molecular imaging and nuclear medicine.

1. Leadership role in the nuclear oncology MOC module
2. NOC is participating in the internship program organized by the SNMMI. The current intern is actively involved in the assessment of NM practice and participation in guidelines development of NCCN.
3. In furtherance of the SNMMI Strategic Plan, the NOC will participate in and provide expertise for the General Nuclear Medicine Task Force.

4. Continue to maintain the Young Investigator Awards established to support the attendance at the Annual Meeting for young investigators, who will be presenting works related to the diagnostic or therapeutic aspects of oncology. A young investigator is defined as an individual within 7 years of PhD or Board certification.

5. Based upon the educational symposium at the oncology meetings, to develop a group that will support Chapter meetings with speakers on topics related to nuclear oncology.

6. Increase technologist involvement in the Council particularly with respect to the development of programs specifically for technologist training in radioisotope therapy.

7. Developing the NOC website will continue. This will be a primary resource for the nuclear medicine community, for oncologists, and for the lay public explaining the role of oncological nuclear medicine in the management of patients with cancer. The site should provide an overview of the principles and current practice of radioisotope therapy, and provide links to appropriate websites where additional information can be found.

8. Continued free membership in the NOC for SNMMI members in training (physicians and technologists)

9. Continue the award given to a technologist and a technologist in training who present an abstract at the Annual Meeting.

10. To improve and increase participation and interactive sessions with other councils and committees, and other organizations.

11. The primary long-term goal will be to encourage participation of in-training physicians, technologists and physicists, as well as the continued renewal of membership by existing members.

12. Promote closer interactions with other SNMMI councils and centers with similar goals such as CMIIT, PET Center of Excellence, and Radiopharmaceutical Sciences Council, as well as the MIRD committee and develop joint educational programs and development of biomarkers for molecular imaging.

13. The NOC will continue its collaborative relationship with WARMTH and has asked that a representative be listed as an ex-officio member of the Board of Directors to further that goal.

7) **Budget and Resource Requirements**

   a. **Summary of Financial Needs**
      The attached budget summarizes the total resources needed to accomplish all of the goals set forth in the business plan.

   b. **Resource Requirements**
      No additional staff, materials, technology, or marketing support is required beyond the usual support provided by SNMMI headquarters.